AAD Updates AD Guidelines With Four New Treatment Picks
The American Academy of Dermatology (AAD) recently issued a focused update to its guidelines on the management of atopic dermatitis (AD) in adults, strongly recommending four recently approved therapies: tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab (in combination with topical therapy). These additions reflect high-certainty evidence supporting both efficacy and safety, according to the workgroup's systematic review published in the Journal of the American Academy of Dermatology .
Robert Sidbury, MD
Asked to comment on the updates, one of the authors, Robert Sidbury, MD, cochair of the guideline committee and chief of dermatology at Seattle Children's Hospital, Seattle, called the rapid need for a guideline update 'a reflection of the extraordinary progress in AD care that is ongoing and is indeed revolutionizing care.' Having 'two new nonsteroidal topical therapies is quite significant,' he added in an interview with Medscape Dermatology . 'Patients have long been dissatisfied with topical options, which have been shackled by safety concerns, some real, some not, and intolerance, such as application site stinging.'
The update comes just over a year after the release of AAD's 2023-2024 adult AD guidelines on treatment with topical and systemic therapies, underscoring the rapid pace of therapeutic development for AD. The update was initiated following the FDA approval of multiple new therapies and newly published high-certainty evidence supporting their use, prompting the AAD to incorporate this data into its existing guidance, according to the authors.
Strong Recommendations for Four New Agents
The guideline workgroup applied the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework to assess new data and formulate treatment recommendations. According to the authors, all four therapies received 'strong' recommendations based on high-certainty evidence:
Tapinarof cream 1% : A nonsteroidal aryl hydrocarbon receptor agonist approved in 2024 for moderate to severe AD. In four trials (n = 1169), once-daily use over 8-12 weeks resulted in statistically and clinically significant improvements in investigator's global assessment (IGA), eczema area and severity index (EASI)-75, and itch scores.
: A nonsteroidal aryl hydrocarbon receptor agonist approved in 2024 for moderate to severe AD. In four trials (n = 1169), once-daily use over 8-12 weeks resulted in statistically and clinically significant improvements in investigator's global assessment (IGA), eczema area and severity index (EASI)-75, and itch scores. Roflumilast cream 0.15% : A phosphodiesterase-4 inhibitor approved in 2024 for mild to moderate AD. Clinical trials (n = 1427) demonstrated significant improvements in IGA and EASI-75 after 4 weeks.
: A phosphodiesterase-4 inhibitor approved in 2024 for mild to moderate AD. Clinical trials (n = 1427) demonstrated significant improvements in IGA and EASI-75 after 4 weeks. Lebrikizumab : An interleukin (IL)-13-targeting monoclonal antibody approved in 2024 for moderate to severe AD. In over 1700 patients, treatment with or without topical corticosteroids led to marked improvements in clinical and patient-reported outcomes.
: An interleukin (IL)-13-targeting monoclonal antibody approved in 2024 for moderate to severe AD. In over 1700 patients, treatment with or without topical corticosteroids led to marked improvements in clinical and patient-reported outcomes. Nemolizumab (with topical therapy): An IL-31 receptor inhibitor approved in 2024 for patients aged 12 years or older inadequately controlled with topical therapies. In three trials (n = 1256), nemolizumab plus topical corticosteroids (with or without topical calcineurin inhibitor) led to significant reductions in itch and improvements in EASI-75 and Dermatology Life Quality Index.
Updated Treatment Algorithm
The guideline includes an updated treatment algorithm to help clinicians integrate these agents into clinical practice. It emphasizes:
All four newly recommended therapies are indicated with strong recommendation symbols in the updated algorithm figure.
Real-World Considerations
Sidbury emphasized that having multiple high-certainty options creates new opportunities but also new challenges in decision-making. 'Such choice is a lovely problem to have,' he said, but he urged clinicians to look beyond efficacy. For example, 'a patient with baseline ocular difficulties would want to be aware that IL-4/13 or IL-13 biologics can cause or exacerbate conjunctivitis,' he explained. 'Nemolizumab or a JAK inhibitor, neither of which carries ocular risk, might be a good choice. Similarly, patients with cardiovascular risk may want to avoid JAK inhibitors due to their boxed warning.'
Treatment selection, he said, should be rooted in shared decision-making: 'It's important to weigh evidence alongside a patient's comorbidities, preferences, and tolerability history.'
Remaining Gaps and Considerations
Despite the promising data, the authors acknowledged important limitations. Most trials were short-term (≤ 24 weeks), and the long-term safety, durability of response, and comparative effectiveness of these agents remain unknown.
Cost is another factor. The authors noted, 'costs for the considered therapies may be prohibitive without adequate insurance coverage.' As such, they stressed the importance of a shared decision-making process that weighs efficacy, safety, and affordability.
Clinical Impact and Future Directions
The update is expected to have an immediate impact in clinical settings. 'Atopic dermatitis care has long been an 'off-label' affair,' Sidbury said. 'Prior to 2017, the only FDA-approved systemic therapy for AD was systemic steroids. Since then, we've seen numerous novel topical and systemic therapies approved with many more on the way. Better evidence plus more choices equals improved outcomes.'
Still, more research is needed. Sidbury pointed to the importance of identifying which therapies may work best for specific patient subtypes — by age, race, gender, or AD phenotype. 'We don't know yet, but the answer is likely yes. This gets at personalized medicine — and that's where we're headed,' he said, noting that future treatment may be guided by inflammatory signatures or genotyping.
While this focused update offers valuable clarity on incorporating new treatment options for adult AD, further research is needed, according to the authors. The workgroup called for real-world data, head-to-head trials, and longer-term outcome studies. The authors also noted pediatric guideline updates are expected in a future publication.
This study was funded in total by internal funds from the American Academy of Dermatology. Sidbury disclosed he serves as an advisory board member for Pfizer, receiving honoraria; as a principal investigator for Regeneron, receiving grants and research funding; as an investigator for Brickell Biotech, and Galderma USA, receiving grants and research funding; and as a consultant for Galderma Global and Microes, receiving fees or no compensation. Other authors reported having financial disclosures with many pharmaceutical companies.
: Biologics, JAK inhibitors, and immunosuppressants remain key choices for refractory disease.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
44 minutes ago
- Medscape
Pushing for PA Modernization
The US — as well as the world at large — is facing a growing healthcare provider shortage. Recent projections, in fact, suggest that the US will be short by more than 3 million healthcare workers by next year, which will have significant impact on the country's ability to provide timely and effective patient care. To help fill this gap, many states are pursuing new legislation to modernize physician associate (PA) practice, allowing PAs to work at the top of their knowledge, experience, and skillset. Medscape continually surveys physicians and other medical professionals about key practice challenges and current issues, creating high-impact analyses. For example, the Physician Assistant Burnout & Depression report found that A lack of control and autonomy contribute to burnout for 1 in 6 PAs. There is often a divide in burnout recognition and management by administrators. Fewer government regulations would help 12% of practicing PAs, and greater respect from admin, colleagues, and staff would help 38% with their burnout. 'Across the country, we are seeing a growing number of legislators express a stronger understanding of the critical role that PAs play in today's healthcare system,' said Chantell Taylor, chief of public affairs and advocacy at the American Academy of Physician Associates (AAPA). 'Today, an estimated 79 million Americans lack adequate access to primary care services. Even worse, 123 million Americans lack adequate access to mental health services…Modernizing PA practice laws aims to address the problem of too few healthcare providers and mounting patient care needs.' Over the past few years, PA organizations in various states have pushed for policy changes to make it easier for patients to access the care they need, including support for the PA Licensure Compact, PA title change, and the removal of unnecessary supervisory requirements. Going Where Providers are Needed Most Several states face greater provider shortages than others. Tennessee, New York, and Oregon, for example, are all expected to see future shortages. PAs could help — yet, moving between states, historically, has required these essential healthcare providers to apply to the state's licensing board, potentially take a required exam, and pay fees. This often makes it harder for PAs to relocate where they are most needed. Over the past two and a half years, however, 17 states have joined the PA Licensure Compact, which facilitates multi-state practice for PAs. Several other states, including North Carolina and Oregon, have filed legislation to join the compact. 'PAs with unencumbered licenses in one compact state will be able to provide care to patients in other compact states,' said Taylor. 'This can be especially beneficial for rural communities and/or areas where healthcare providers are few and far between.' A PA by Any Other Name In 2024, Oregon became the first state to legally change the title of 'physician assistant' to PA. In summer 2025, both Maine and New Hampshire also enacted new laws to promote a title change. Kathleen Moneghan, a PA from Maine, said this legislation was important to challenge ongoing misconceptions about what PAs do — and help facilitate future practice modernization efforts. 'I remember when I first graduated as a PA and I was seeing patients, they'd say, 'Oh, when am I going to see the doctor?'' she explained. 'They thought what we do is assist the doctor, when, in reality, we see patients on our own. We have our own patient panels, we treat, we diagnose, we prescribe. Having the right title creates a better understanding for patients about what we do — and also helps ensure they trust the care we give to them.' Removing Physician Supervision Taylor said that there is growing support across multiple states for new laws to remove supervision requirements for experienced PAs. Historically, PAs needed to sign a contract with a physician to 'supervise' their work or participate in a collaboration agreement. But Sarah Leslie, a PA in New Hampshire, said that such requirements are costly and onerous. Worse, they often led to PAs losing their jobs when doctors refused to do the paperwork because of liability concerns. 'Most of these doctors weren't even in the office with us, despite the fact they were tied to our license. They weren't even supervising,' she explained. 'And there are so many stories about PAs being let go. I know of literally an entire family practice office that got rid of all of their PAs because the doctor didn't want to sign the forms.' The need for a supervising physician could also be quite expensive for PAs who needed a supervising physician to keep their practice doors open. 'I was paying $1000 a month to a doctor who wasn't even in the practice to just sign a piece of paper,' Leslie said. 'Doctors and medical societies often say things like, 'Without supervision, PAs are going to start doing open heart surgery in the cafeteria,' but when we talked to legislators about what we really do and how we can improve access, they saw the value in us being able to practice without this kind of paperwork.' Now, the state of New Hampshire has enacted new legislation to remove those supervisory requirements. When a PA has reached 8000 postgraduate clinical hours, PAs can own and run their own practice. Other states, including Iowa, Montana, Wyoming, and Colorado, have done the same — and many have already seen tangible benefits from removing or relaxing supervisory requirements, said Taylor. 'Following supervision removal in Iowa, a PA operating a mental health clinic was able to drastically improve access to care for patients. She redirected funding that had been used on supervision to hire more providers,' Taylor said. 'In 2024 alone, her clinic saw more than 800 new patients, the vast majority of whom were able to get a mental health appointment within 2 weeks.' Pushing for Quality and Safety Both Moneghan and Leslie are continuing to push for PA practice modernization in their states. They see it as essential to helping provide the vital healthcare Americans will need in the years to come. And, as research thus far shows, these changes are enhancing care, not negatively affecting patient safety as some physician organizations have argued. Taylor hopes that more states will see the value in enacting laws that allow PAs to do their jobs. 'To date, there has been no research or evidence provided that shows that quality or safety of care declines, or malpractice rates increase, when PA supervision is removed,' Taylor said. 'What has been proven is that providers can practice in a manner consistent with their experience, training, and education, and patients can better access the high-quality healthcare they deserve.'
Yahoo
an hour ago
- Yahoo
NORTHEAST GEORGIA MEDICAL'S LEVEL I TRAUMA CENTER ENROLLS 170TH PATIENT FOR PRYTIME MEDICAL'S INTERNATIONAL STUDY
GAINESVILLE, Ga., June 27, 2025 /PRNewswire/ -- When patients arrive at Northeast Georgia Medical Center (NGMC) in Gainesville with traumatic injuries, they're not only receiving the most advanced, expert care – they're helping to improve health care for people around the world. NGMC recently enrolled the 170th patient in the Partial REBOA Outcomes Multicenter ProspecTive (PROMPT) study, which shares data to improve outcomes for those critically injured patients. A pREBOA-PRO™ catheter was used to control life-threatening bleeding in the 170th patient, who arrived at the hospital's Level I Trauma Center, following a blunt trauma injury. The intervention stabilized the patient, reduced the need for additional blood products and ultimately saved their life. The trauma team at NGMC Gainesville routinely performs partial aortic occlusion – restricting blood flow through the aorta, the largest artery in the body – using the pREBOA-PRO™ device. As part of the PROMPT study, the team shares data on the use of the device to help advance clinical care. "When someone experiences a traumatic injury, every second matters," said Michael Cormican, MD, trauma surgeon at NGMC Gainesville. "We are grateful for the opportunity to support research that can lead to better outcomes for trauma patients." The international PROMPT study, funded by the Department of Defense, aims to ultimately enroll 340 patients across nine selected centers. NGMC patients who meet the study criteria are automatically enrolled. To learn more about NGMC's trauma program, visit ABOUT NORTHEAST GEORGIA MEDICAL CENTER Since 1951, Northeast Georgia Medical Center (NGMC) has been on a mission of improving the health of our community in all we do. With hospitals located in Gainesville, Braselton, Winder and Dahlonega, the four NGMC campuses have a total of more than 750 beds and more than 1,200 medical staff members representing more than 60 specialties. NGMC is part of Northeast Georgia Health System, a non-profit that cares for more than one million people across more than 19 counties. Learn more at ABOUT PRYTIME MEDICAL, INC. The pREBOA-PRO™ device is a product of Prytime Medical Inc, a leading innovator and global provider of lifesaving endovascular occlusion products. Prytime was selected by the U.S. Army Medical Research and Development Command to receive nearly $6 million from the U.S. Department of Defense awarded through the Medical Technology Enterprise Consortium. ABOUT U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND The U.S. Army Medical Research and Development Command is the Army's medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense. ABOUT MTEC The Medical Technology Enterprise Consortium is a 501(c)(3) biomedical technology consortium that is internationally-dispersed, collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Development Command. The consortium focuses on the development of medical solutions that protect, treat, and optimize the health and performance of U.S. military personnel and civilians. To find out more about MTEC, visit Disclaimer: The views and conclusions contained herein are those of the authors and should not be interpreted as representing the official policies or endorsements, either expressed or implied, of U.S. Government. CONTACT: Courtney Randolph, Public Relations & MarketingNortheast Georgia Medical Center743 Spring Street NE, Gainesville, GA 30501770-219-3840 | View original content to download multimedia: SOURCE Prytime Medical
Forbes
an hour ago
- Forbes
National HIV Testing Day Commemorates 30th Anniversary
LOS ANGELES - APRIL 28: A motorhome converted into a mobile HIV screening lab by the AIDS ... More Healthcare Foundation (AHF) is parked on a busy street on its first day of operations on April 28, 2004 in Los Angeles, California. The test reports a client's HIV status in only 20 minutes with accuracy reportedly greater than 99 percent using a single drop of blood drawn from the finger. AHF gives same-day counseling and support to walk-in clients who test positive to HIV. Rapid testing solves the problem of large numbers of people not returning for their test results from older methods that take as long as two week to return results. California's multi-billion dollar pornography industry is currently in a voluntary 60-day moratorium following the recent HIV infection of two porn stars who had been in sexual contact with dozens of people in the adult entertainment industry. (Photo by) Since 1995, National HIV Testing Day has provided a platform to raise awareness and confront stereotypes about HIV in the United States. The theme for 2025's Testing Day is 'Level up your self-love: check your status.' What is HIV? HIV is the acronym for human immunodeficiency virus. The initial symptoms of HIV resemble many other illnesses: chills, fatigue, fever, swollen lymph nodes, etc. In fact, some people may not know that they are positive for HIV because they may not have developed noticeable health symptoms at all. According to stats published by around half the amount of polled young people, ages 13-24, did not know if they were positive for HIV. In the same poll, around 30% of adults, ages 25-34, reported that they also did not know their HIV health status. If a person has HIV but hasn't been diagnosed, that person can unknowingly transmit the virus to others. Many medical professionals recommend routine HIV tests, especially for patients who already undergo STI screenings. Routine HIV testing can help diagnose an infection as early as possible. This prompt detection can ensure that an HIV-positive person can receive medical treatments to prevent HIV from advancing into AIDS. A common misconception conflates HIV and AIDS, or acquired immunodeficiency syndrome. As HIV enters its advanced stages, it can result in worsening damage to a patient's immune system. However, early diagnosis and antiretroviral (ARV) treatment can prevent HIV from developing into the more dangerous condition of AIDS. There is no current cure for HIV; however, the CDC emphasizes that 'people with HIV who get on and stay on effective HIV treatment can live long, healthy lives and protect their partners.' HIV can only spread through bodily fluids like breast milk, blood, semen, rectal, and vaginal fluids. Unprotected sex is a common method of transmission for HIV. Men who have anal sex with other men have historically been identified as experiencing a higher risk of potentially coming into contact with HIV. However, a person's sexual orientation is not innately a risk factor. Any person who experiences anal fissures or vaginal dryness might experience bleeding or minor tearing during unprotected sex. These damaged tissues can increase the risk of transmitting HIV because bodily fluids may come into contact with your mucus membrane. While HIV is often transmitted through sexual contact, there are other ways that the virus can spread. Contaminated needles can expose people to HIV. Mothers with HIV may transmit the virus to their children through breastfeeding. What Are Prevention and Testing Options? You can lower your risk for HIV and other illnesses by taking the following actions: - Use condoms and dental dams - Use medical-grade, sterile needles - Never share needles with other people, and never inject yourself with a needle someone else has already used - Disposing of medical equipment safely to avoid accidental needle pricks - Getting routinely tested for HIV Condoms are an effective tool for preventing the transmission of HIV because condoms limit your exposure to bodily fluids. According to a study published in the Journal of Acquired Immune Deficiency Syndromes, condoms are between 70%-80% effective at preventing the spread of HIV. If you worry that you may be at risk, you might consider a preventative treatment like Pre-Exposure Prophylaxis, or PrEP. For over ten years, PrEP has helped prevent patients from developing HIV. If you are interested in testing options, consult with your doctor or your local health department. On National HIV Testing Day, many pharmacies (including participating Walgreens locations across America) offer free rapid HIV tests and other resources.
